Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L7 pseudogene 42 (RPL7P42) is a processed pseudogene, meaning it is a nonfunctional genomic DNA sequence derived from the functional ribosomal protein L7 gene (RPL7)[3][6]. Pseudogenes like RPL7P42 do not encode functional proteins and typically do not have direct biological activity, therapeutic targeting utility, or disease associations. The parent gene, RPL7, encodes a component of the 60S ribosomal subunit, but the pseudogenes are generally considered "genomic fossils" without protein-coding capacity or druggability[6]. As such, ribosomal protein L7 pseudogene 42 is not recognized as a therapeutic target, nor does it have known aliases, biological functions, disease associations, or drug interactions relevant to clinical or pharmacological fields[3][6]. Additional notes: - This is a non-functional pseudogene, not a protein, receptor, or drug target. - The biological and disease roles, mechanisms of action, and related features apply only to the canonical, functional RPL7 gene and not to its pseudogenes. - There is nothing intrinsically "wrong" with the spelling or synonym, but as a pseudogene it is not an actionable therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7 pseudogene 42 (RPL7P42).